Standard BioTools (STU:FLB) Retained Earnings: €-1,007.09 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FLB Standard BioTools Inc STU:FLB
37 GF Score
Price €0.69
GF Value €0.60
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Retained Earnings?

Standard BioTools STU:FLB +2.22% 37 Retained Earnings is €-1,007.09 Mil as of Jun. 2026. GuruFocus rates STU:FLB with a GF Score™ of 37/100 and a GF Value™ of €0.60 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Standard BioTools's retained earnings for the quarter that ended in Jun. 2026 was €-1,007.09 Mil.

Standard BioTools's quarterly retained earnings increased from Dec. 2025 (€-1,076.51 Mil) to Mar. 2026 (€-980.46 Mil) but then declined from Mar. 2026 (€-980.46 Mil) to Jun. 2026 (€-1,007.09 Mil).

Standard BioTools's annual retained earnings declined from Dec. 2023 (€-917.69 Mil) to Dec. 2024 (€-1,132.30 Mil) but then increased from Dec. 2024 (€-1,132.30 Mil) to Dec. 2025 (€-1,076.51 Mil).


Standard BioTools  (STU:FLB) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Standard BioTools Retained Earnings Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Retained Earnings Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only -651.36 -874.24 -917.69 -1,132.30 -1,076.51

Standard BioTools Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,079.54 -1,090.42 -1,076.51 -980.46 -1,007.09
STU:FLB
37GF Score
Standard BioTools Inc STU:FLB
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of €-1,007.09 Mil mean?
Standard BioTools (STU:FLB) has a Retained Earnings of €-1,007.09 Mil as of Jun. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' Retained Earnings too high?
Standard BioTools' current Retained Earnings is €-1,007.09 Mil. Overall, Standard BioTools has a GF Score™ of 37/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Retained Earnings compare to CV and ELMD?
Standard BioTools' Retained Earnings of €-1,007.09 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Standard BioTools and its competitors. Standard BioTools's current Retained Earnings is €-1,007.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Modestly Overvalued. The stock's GF Value™ is €0.60, compared to a current price of €0.69 — trading 14.2% above its estimated fair value. The current Retained Earnings is €-1,007.09 Mil. Standard BioTools' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Retained Earnings is €-1,007.09 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (STU:FLB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued. The current stock price of €0.69 is trading 14.2% above its estimated GF Value™ of €0.60. GuruFocus considers Standard BioTools to be Modestly Overvalued.

Key valuation signals for STU:FLB:

  • Retained Earnings: €-1,007.09 Mil
  • GF Value™: €0.60 vs. price of €0.69 (14.2% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Standard BioTools Business Description

Other Exchanges LAB:USA
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
37GF Score

Get the complete analysis for STU:FLB

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.69
Price
€0.60
GF Value